Inhibitory Effects of Etomidate and Ketamine on Adenosine Triphosphate–Sensitive Potassium Channel Relaxation in Canine Pulmonary Artery Ju-Tae Sohn, M.D.,* Paul A

Total Page:16

File Type:pdf, Size:1020Kb

Inhibitory Effects of Etomidate and Ketamine on Adenosine Triphosphate–Sensitive Potassium Channel Relaxation in Canine Pulmonary Artery Ju-Tae Sohn, M.D.,* Paul A Anesthesiology 2003; 98:104–13 © 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Inhibitory Effects of Etomidate and Ketamine on Adenosine Triphosphate–Sensitive Potassium Channel Relaxation in Canine Pulmonary Artery Ju-Tae Sohn, M.D.,* Paul A. Murray, Ph.D.† Background: The authors recently demonstrated that etomi- diseases, including essential hypertension, angina pecto- date and ketamine attenuated endothelium-dependent pulmo- ris, myocardial ischemia, and cerebral vascular disease.4 -nary vasorelaxation mediated by nitric oxide and Ca2؉-acti -؉ Investigators in our laboratory and others have demon vated K channels. In the current study, they tested the ϩ hypothesis that these intravenous anesthetics inhibit pulmo- strated that K ATP channel agonists can cause marked Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/98/1/104/405921/0000542-200301000-00019.pdf by guest on 24 September 2021 nary vasorelaxation mediated by adenosine triphosphate–sen- pulmonary vasodilation, which is reversed by gliben- sitive potassium (K؉ ) channel activation. ϩ 5–13 ATP clamide, a specific K ATP channel inhibitor. More- Methods: Endothelium intact and denuded pulmonary arte- over, endogenous Kϩ channel–induced vasodilation rial rings were suspended in organ chambers for isometric ATP tension recording. The effects of etomidate (5 ؋ 10؊6 and 5 ؋ is functionally significant, because it has been shown to ؊ ؊ ؊ M) and ketamine (5 ؋ 10 5 and 10 4 M) on vasorelaxation modulate the pulmonary vasoconstrictor response to 5 10 ؉ 14 7 responses to lemakalim (K ATP channel activator), prostacy- hypoxia and systemic hypotension. clin, and papaverine were assessed in phenylephrine-precon- Kϩ channels are present not only in vascular smooth tracted rings. The effect of cyclooxygenase inhibition with in- ATP domethacin was assessed in some protocols. muscle cells, but also have been demonstrated in systemic ϩ ؊6 15,16 Results: Etomidate (5 ؋ 10 M) only inhibited the vasorelax- vascular endothelial cells. In endothelial cells, K ATP ant response to lemakalim in endothelium intact rings, whereas channel activation results in hyperpolarization, an increase ؋ ؊5 ϩ a higher concentration of etomidate (5 10 M) inhibited in Ca2 influx, and the production of endothelium-derived relaxation in both intact and endothelium-denuded rings. Pre- 17,18 treatment with indomethacin abolished the endothelium-de- vasodilators, such as nitric oxide and prostacyclin. We pendent attenuation of lemakalim-induced relaxation caused by have recently demonstrated that lemakalim-induced pulmo- ؊ ؊ etomidate. Ketamine (5 ؋ 10 5 and 10 4 M) inhibited the relax- nary vasorelaxation involves both endothelium-dependent ation response to lemakalim to the same extent in both endo- and vascular smooth muscle components.19 The endothe- thelium-intact and -denuded rings, and this effect was not pre- lium-dependent component of lemakalim-induced vasore- vented by indomethacin pretreatment. Etomidate and ketamine had no effect on the relaxation responses to prostacyclin or laxation is mediated by a vasodilator metabolite of the 19 ϩ papaverine. cyclooxygenase pathway. Moreover, K ATP channels me- Conclusions: These results indicate that etomidate, but not diate a synergistic interaction between nitric oxide and ketamine, attenuates the endothelium-dependent component of prostacyclin in response to some endothelium-dependent lemakalim-induced pulmonary vasorelaxation via an inhibitory 20 effect on the cyclooxygenase pathway. Both anesthetics inhibit agonists (e.g., bradykinin). ؉ K ATP-mediated pulmonary vasorelaxation via a direct effect on Etomidate and ketamine are intravenous anesthetics pulmonary vascular smooth muscle. that are recognized to have minimal effects on clinically measured endpoints of cardiovascular function. Thus, ϩ ADENOSINE triphosphate-sensitive potassium (K ATP) they are often used as induction agents in patients with channels have been identified in pulmonary arterial hemodynamic instability. Our laboratory has recently 1 ϩ smooth muscle. K ATP channel activation results in demonstrated that etomidate and ketamine attenuated ϩ membrane hyperpolarization and a decrease in Ca2 pulmonary vasorelaxant responses to bradykinin and ϩ influx through voltage-dependent Ca2 channels, which acetylcholine by inhibiting both nitric oxide and Ca2ϩ- in turn reduces vascular smooth muscle tone. Kϩ ϩ ATP activated potassium channel (K Ca)-mediated compo- channels are known to be activated by hyperpolarizing nents of the response.21 However, the effects of these agonists, such as diazoxide, pinacidil, cromakalim, and anesthetics on Kϩ -mediated pulmonary vasorelax- 2,3 ϩ ATP its enantiomer, lemakalim. K ATP channel agonists are ation have not been investigated. An anesthesia-induced used as therapeutic agents in a variety of cardiovascular attenuation of pulmonary vasodilator mechanisms could increase right ventricular afterload, which could ad- * Research Fellow. † Carl E. Wasmuth Endowed Chair and Director. versely affect patients with right ventricular dysfunction. Received from the Center for Anesthesiology Research, Division of Anesthe- The first goal of this in vitro study was to investigate siology and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, the effects of etomidate and ketamine on the pulmonary Ohio. Submitted for publication May 9, 2002. Accepted for publication August ϩ 15, 2002. Supported by grants No. HL-38291 and HL-40361 from the National vasorelaxant response to the K ATP agonist lemakalim. Heart, Lung and Blood Institute, Bethesda, Maryland. Presented in part at the Based on our previous results,19,21 we tested the hypoth- annual meeting of the American Society of Anesthesiologists, New Orleans, Louisiana, October 16, 2001. esis that these anesthetics would attenuate the endothe- Address reprint requests to Dr. Murray: Center for Anesthesiology Research, lium-dependent component of lemakalim-induced relax- FF40, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio ation. We also tested the hypothesis that the inhibitory 44195. Address electronic mail to: [email protected]. Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org. effects of etomidate and ketamine involved a decrease in Anesthesiology, V 98, No 1, Jan 2003 104 ϩ ETOMIDATE AND KETAMINE INHIBIT K ATP RELAXATION 105 the production or activity of vasodilator metabolites of Isometric Tension Experiments the cyclooxygenase pathway. Pulmonary arterial rings were vertically mounted be- tween two stainless steel hooks in organ baths filled with 25 ml Krebs-Ringer bicarbonate solution (37°C) gassed with 95% O and 5% CO . One of the hooks was an- Material and Methods 2 2 chored and the other was connected to a strain gauge to measure isometric force. The rings were stretched at All experimental procedures and protocols were ap- 10-min intervals in increments of 0.5 g to achieve opti- proved by the Institutional Animal Care and Use Com- mal resting tension. Optimal resting tension was defined mittee of the The Cleveland Clinic Foundation. as the minimum amount of stretch required to achieve the largest contractile response to 40 mM KCl and was Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/98/1/104/405921/0000542-200301000-00019.pdf by guest on 24 September 2021 Preparation of Pulmonary Arterial Rings determined in preliminary experiments to be 5 g for the Thirty healthy mongrel dogs weighing 20–30 kg were size of the arteries used in these experiments. After the anesthetized with intravenous pentobarbital sodium arterial rings had been stretched to their optimal resting (30 mg/kg) and intravenous fentanyl citrate (15 ␮g/kg). tension, the contractile response to 60 mM KCl was After tracheal intubation, the lungs were mechanically measured. After washing out KCl from the organ bath ventilated. A catheter was placed in the right femoral and the return of isometric tension to prestimulation artery, heparin (8,000 units) was administered intrave- values, a cumulative concentration–response curve to nously, and the dogs were exsanguinated by controlled phenylephrine was performed in each ring. This was hemorrhage. A left lateral thoracotomy was performed achieved by increasing the concentration of phenyleph- Ϫ8 Ϫ5 through the fifth intercostal space, and the heart was rine in half-log increments (from 10 M to 3 ϫ 10 M) arrested with induced ventricular fibrillation (Grass In- after the response to each preceding concentration had strument Co., Quincy, MA). The heart and lungs were reached a steady state. This allowed us to calculate the removed from the thorax en bloc, and the lower right dose required to achieve 50% of the maximum response and left lung lobes were dissected free. Intralobar pul- to phenylephrine (ED50) in each ring. All rings were ␤ monary arteries (2–4 mm ID) were carefully dissected pretreated with the -adrenoreceptor antagonist pro- ϫ Ϫ6 and immersed in cold modified Krebs-Ringer bicarbon- pranolol (5 10 M, incubated for 30 min) before ate solution composed of 118.3 mM NaCl, 4.7 mM KCl, phenylephrine administration in all protocols to avoid the ␤-agonist effect of phenylephrine. 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2,25mM NaHCO3, 0.016 mM Ca-EDTA, and 11.1 mM glucose. The arteries were cleaned of connective tissue and cut into Experimental Protocols ring segments 4–5 mm in length with special care taken After washout of phenylephrine from the organ bath not
Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A A–803467, 98 Absorption, Distribution, Metabolism, Elimination
    Index A Anxiety disorders, 55 A–803467, 98 APD. See Action potential duration Absorption, distribution, metabolism, Arrhythmias, 45, 46 elimination and toxicity Aryl sulfonamido indanes, 126–128, 130 (ADMET), 193 ATP-sensitive potassium channels (KATP Absorption, distribution, metabolism, channels), 61 excretion, and toxicity Atrial effective refractory period (AERP), 122, (ADMET), 68 124–126, 128, 129, 132, 138 Acetylcholine binding protein (AChBP), Autoimmune diseases, 254 61, 62, 64 AZD7009, 101 Acetylcholine receptor (AChR), 57, 64 Azimilide, 139 Action potential duration (APD), 120, 122, 123, 128, 132 B Action potentials, 243, 256, 259 Basis set, 69–70 ADME/T, 299, 304 b-Barrel membrane proteins AERP. See Atrial effective refractory period genome-wide annotation, 13 Agitoxin (AgTX), 60 machine-learning techniques Agonists, 59–61, 64 residue pair preference, 11 Alinidine, 40–42 TMBs, 10 ALS. See Amyotrophic lateral sclerosis pipeline, genomic sequences, 14 Alzheimer, 55, 61 statistical method, 9–10 AMBER, 61, 65 Bending hinge, 64 2-Amino–2-imidazolidinone, 123, 125 Benzanilide, 256–257 Ammi visnaga, 254 Benzimidazolone, 256–257 b-Amyloid peptide (Ab), 62–63, 65 Benzocaine, 140 Amyotrophic lateral sclerosis (ALS), 90, 94, Benzodiazepines, 245 101 Benzopyrane, 127–128 Anionic channel blockers Benzopyrans, 61, 246–251, 261 mechanism of action of, 329–330 Benzothiadiazine 1,1-dioxide, 252–254 Antagonists, 59, 60 Benzothiadiazines, 253 Antiarrhythmic, 65–66, 68, 99, 101 Benzothiazepine, 70 Antiarrhythmic agents Benzothiazine derivatives, 251–252 class I, 245 Benzotriazole, 256–257 class II, 245 Bestrophins, 321, 322, 330, 331 class III, 245 Big potassium channels (BK channels), Antidepressant, 65–67 256, 257 Antiepileptic, 46 Bupivacaine, 56, 58, 59, 64, 69, 140 S.P.
    [Show full text]
  • Ep 0681833 B1
    Europäisches Patentamt *EP000681833B1* (19) European Patent Office Office européen des brevets (11) EP 0 681 833 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 9/14, A61K 9/18 of the grant of the patent: 13.06.2001 Bulletin 2001/24 (21) Application number: 95106396.5 (22) Date of filing: 28.04.1995 (54) Nasally administrable compositions Nasal verabreichbare Mittel Compositions administrables par voie intranasale (84) Designated Contracting States: (74) Representative: Kraus, Walter, Dr. et al AT BE CH DE DK ES FR GB IT LI LU NL PT SE Patentanwälte Kraus, Weisert & Partner Thomas-Wimmer-Ring 15 (30) Priority: 11.05.1994 JP 12077894 80539 München (DE) 02.03.1995 JP 6664095 (56) References cited: (43) Date of publication of application: EP-A- 0 588 255 EP-A- 0 648 498 15.11.1995 Bulletin 1995/46 • DATABASE WPI Week 9344, Derwent (73) Proprietor: DOTT RESEARCH LABORATORY Publications Ltd., London, GB; AN 93-348353 Yokohama-shi, Kanagawa 224 (JP) ’Pharmaceutical compsn. for admin. via blood vessels - contains microcrystalline calcium (72) Inventor: Yanagawa, Akira, Med. Dr. phosphate powder as carrier for e.g. insulin’ & Yokohama-shi, Kanagawa, 224 (JP) JP-A-05 255 095 (ADVANCE K.K.) 5 October 1993 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Neuroprotective Effects of Cromakalim on Cerebral Ischemia-Reperfusion (Ir) Injury and Aluminium Induced Toxicity in Rat Brain
    Innovare International Journal of Pharmacy and Pharmaceutical Sciences Academic Sciences ISSN- 0975-1491 Vol 6, Issue 6, 2014 Original Article NEUROPROTECTIVE EFFECTS OF CROMAKALIM ON CEREBRAL ISCHEMIA-REPERFUSION (IR) INJURY AND ALUMINIUM INDUCED TOXICITY IN RAT BRAIN *1PITHADIA ANAND BHARAT KUMAR, 2SHITAL PANCHAL *1Department of Pharmacology, Parul Institute of Pharmacy, Vadodara,2 Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India. Email: [email protected] Received: 29 Apr 2014 Revised and Accepted: 28 May 2014 ABSTRACT Objective: Preclinical studies have demonstrated that potassium channel openers show a neuroprotective effect on cerebral ischemia-reperfusion (IR) injury in rats. However, their mechanism of action and effects in brain stroke related disorders such as Alzheimer’s disease (AD) remain poorly understood. Hence present study was done to investigate the prophylactic use of the adenosine triphosphate-sensitive (ATP) potassium channel opener cromakalim on neurological function in rats with cerebral IR injury and its related disorders AD. Methods: Male Wistar rats were randomly assigned to 6 groups (n = 36): Normal control, aluminium chloride(AlCl3) control, AlCl3 Sham operated, ischemia reperfusion (IR) control, AlCl3-IR control and AlCl3-IR with cromakalim treatment. Cromakalim10 mg/kg intra peritonially (i.p.) was administered daily for 42 days in middle cerebral artery occluded rats treated with AlCl3. At 24 hours post-surgery, neurological score, brain hemisphere weight difference, brain acetylcholinestarase level, lipid peroxidation, Na+/K+ ATPase pump activity and super oxide dismutase level were measured. Results: Following cerebral ischemia-reperfusion injury along with aluminium chloride, neurological score,brain hemisphere weight difference, brain acetylcholinestarase level, malondialdehyde levels were significantly high while Na+/K+ ATPase pump activity and super oxide dismutase(SOD) levels were significantly lower in diseased animals (P < 0.05).
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,329,697 B2 Garbaccio Et Al
    US008329697B2 (12) United States Patent (10) Patent No.: US 8,329,697 B2 Garbaccio et al. (45) Date of Patent: Dec. 11, 2012 (54) IMIDIZO 1.2-APYRAZINES USEFUL AS (56) References Cited AHCY HYDROLASE INHIBITORS U.S. PATENT DOCUMENTS (75) Inventors: Robert M. Garbaccio, Lansdale, PA 4,507,294 A 3, 1985 Bristol et al. (US); Antonella Converso, Elkins Park, 56.6 f 3.3: Ret , al PA (US); Mark E. Fraley, North Wales, 4. W w Wa (a. PA (US); Timothy J. Hartingh, Blue 2004/0204429 A1 10, 2004 Yuan Bell, PA (US) FOREIGN PATENT DOCUMENTS WO WO 2009/108546 * 9/2009 (73) Assignee: Merck Sharp & Dohme Corp., OTHER PUBLICATIONS Rahway, NJ (US) Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.* (*) Notice: Subject to any disclaimer, the term of this Hackam, et al. JAMA, 296(14), 2006, 1731-1732.* patent is extended or adjusted under 35 * cited b U.S.C. 154(b) by 163 days. c1ted by examiner Primary Examiner — Douglas MWillis (21) Appl. No.: 12/811,911 (74) Attorney, Agent, or Firm — Kenrick L. Vidale; John C. Todaro (22) PCT Filed: Feb. 18, 2009 (57) ABSTRACT (86). PCT No.: PCT/US2O09/034344 The present invention is directed to AHCY inhibitors of for mula (I) which are useful in the treatment of diseases charac S371 (c)(1), terized by high homocysteine levels, such as Alzheimer's (2), (4) Date: Jul. 7, 2010 disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of (87) PCT Pub. No.: WO2009/108546 the compounds and compositions in the treatment of diseases PCT Pub.
    [Show full text]
  • Effect of Niflumic Acid on Noradrenaline-Induced Contractions of the Rat Aorta D.N
    Brifish Journal of Pharmacology (1996) 118, 1065-1071 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 0 Effect of niflumic acid on noradrenaline-induced contractions of the rat aorta D.N. Criddle, R. Soares de Moura, l*I.A. Greenwood & *W.A. Large Departmento de Farmacologia, Centro Biomedico - IB, Universidade do Estado do Rio de Janeiro, Brasil and *Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 ORE 1 The effects of niflumic acid, an inhibitor of calcium-activated chloride channels, were compared with the actions of the calcium channel antagonist nifedipine on noradrenaline-evoked contractions in isolated preparations of the rat aorta. 2 The cumulative concentration-effect curve to noradrenaline (NA) was depressed by both nifedipine and niflumic acid in a reversible and concentration-dependent manner. The degree of inhibition of the maximal contractile response to NA (1 gM) produced by 10 gM niflumic acid (38%) was similar to the effect of 1 gM nifedipine (39%). 3 Contractions to brief applications (30 s) of 1 pM NA were inhibited by 55% and 62% respectively by 10 gM niflumic acid and 1 gM nifedipine. 4 In the presence of 0.1 Mm nifedipine, niflumic acid (10 gM) produced no further inhibition of the NA- evoked contractions. Thus, the actions of niflumic acid and nifedipine were not additive. 5 In Ca-free conditions the transient contraction induced by 1 gM NA was not inhibited by niflumic acid (10 Mm) and therefore this agent does not reduce the amount of calcium released from the intracellular store or reduce the sensitivity of the contractile apparatus to calcium.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Potassium Channel Kcsa
    Potassium Channel KcsA Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone. www.MedChemExpress.com 1 Potassium Channel Inhibitors, Agonists, Antagonists, Activators & Modulators (+)-KCC2 blocker 1 (3R,5R)-Rosuvastatin Cat. No.: HY-18172A Cat. No.: HY-17504C (+)-KCC2 blocker 1 is a selective K+-Cl- (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of cotransporter KCC2 blocker with an IC50 of 0.4 Rosuvastatin. Rosuvastatin is a competitive μM. (+)-KCC2 blocker 1 is a benzyl prolinate and a HMG-CoA reductase inhibitor with an IC50 of 11 enantiomer of KCC2 blocker 1. nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg (3S,5R)-Rosuvastatin (±)-Naringenin Cat. No.: HY-17504D Cat. No.: HY-W011641 (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of (±)-Naringenin is a naturally-occurring flavonoid.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • PJP5'2004.Vp:Corelventura
    Copyright © 2004 by Institute of Pharmacology Polish Journal of Pharmacology Polish Academy of Sciences Pol. J. Pharmacol., 2004, 56, 499508 ISSN 1230-6002 “…I’ll tell you all my ideas about Looking Glass House. First, there’s the room you can see through the glass – that’s just the same as our drawing room, only the thing go other way… Well then, the books are something like our books, only the words go the wrong way; …I wonder if they’d give you milk in there? Perhaps Looking-Glass milk isn’t good to drink…” “Through the Looking Glass” Lewis Caroll (1832–1898) REVIEW INFLUENCE OF THE ABSOLUTE CONFIGURATION ON PHARMACOLOGICAL ACTIVITY OF ANTIHYPERTENSIVE AND ANTIARRHYTHMIC DRUGS Katarzyna Kulig, Piotr Nowicki, Barbara Malawska Department of Pharmaceutical Chemistry, Medical College, Jagiellonian University, Medyczna 9, PL 30-688 Kraków, Poland Influence of the absolute configuration on pharmacological activity of antihypertensive and antiarrhythmic drugs. K. KULIG, P. NOWICKI, B. MALAWSKA. Pol. J. Pharmacol., 2004, 56, 499–508. Chirality is a fundamental property of biological systems and reflects the underlying asymmetry of matter. Interactions of drugs with receptors, en- zymes or binding sites have long been known to be stereoselective, and it is increasingly recognized that both pharmacodynamic and pharmacokinetic events contribute to the overall clinically observed stereoselectivity. The pharmacological activity may reside only in one enantiomer, while the second one may be inactive or have desirable or undesirable activity. Two isomers may be nearly identical both in qualitative and quantitative as- pects of pharmacological activity. The activity of particular enantiomers may differ only at the quantitative level.
    [Show full text]